Investigating Constraints Along the Plant Secretory Pathway to Improve Production of a SARS-CoV-2 Spike Vaccine Candidate.
chaperone
degradation
glycoprotein
molecular farming
processing
protease
vaccine
Journal
Frontiers in plant science
ISSN: 1664-462X
Titre abrégé: Front Plant Sci
Pays: Switzerland
ID NLM: 101568200
Informations de publication
Date de publication:
2021
2021
Historique:
received:
20
10
2021
accepted:
29
11
2021
entrez:
21
1
2022
pubmed:
22
1
2022
medline:
22
1
2022
Statut:
epublish
Résumé
Given the complex maturation requirements of viral glycoproteins and the challenge they often pose for expression in plants, the identification of host constraints precluding their efficient production is a priority for the molecular farming of vaccines. Building on previous work to improve viral glycoprotein production in plants, we investigated the production of a soluble SARS-CoV-2 spike comprising the ectopic portion of the glycoprotein. This was successfully transiently expressed in
Identifiants
pubmed: 35058959
doi: 10.3389/fpls.2021.798822
pmc: PMC8764404
doi:
Types de publication
Journal Article
Langues
eng
Pagination
798822Informations de copyright
Copyright © 2022 Margolin, Verbeek, de Moor, Chapman, Meyers, Schäfer, Williamson and Rybicki.
Déclaration de conflit d'intérêts
EM, RC, AM, A-LW, and ER have filed a series of patent applications encompassing approaches to produce viral glycoproteins in plants, including for SARS-CoV-2: US 2019/0337994 A1, WO 2018 220,595 A1, PA174002_PCT, and PA2106659.4. AM and ER are shareholders in Cape Bio Pharms (SA) Pty. Ltd., a molecular farming company in Cape Town. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7348-E7357
pubmed: 28807998
PLoS Pathog. 2021 Apr 9;17(4):e1009501
pubmed: 33836016
Trends Biotechnol. 2020 Sep;38(9):1034-1044
pubmed: 32818443
Nat Rev Microbiol. 2020 Dec;18(12):690-704
pubmed: 32913297
Vaccines (Basel). 2021 Sep 01;9(9):
pubmed: 34579215
Plant Biotechnol J. 2015 Oct;13(8):1180-90
pubmed: 26387511
Lancet. 2020 Nov 7;396(10261):1491-1503
pubmed: 33065035
Front Plant Sci. 2020 Dec 03;11:609207
pubmed: 33343609
Science. 2020 Aug 21;369(6506):956-963
pubmed: 32540903
Lancet. 2021 Mar 13;397(10278):1023-1034
pubmed: 33587887
Plant Biotechnol J. 2018 Oct;16(10):1797-1810
pubmed: 29509983
Plant Biotechnol J. 2018 Jun 11;:
pubmed: 29890031
Plant Biotechnol J. 2015 Feb;13(2):235-45
pubmed: 25283551
Viruses. 2021 Aug 12;13(8):
pubmed: 34452461
Nat Med. 2021 Jun;27(6):1071-1078
pubmed: 34007070
FEBS Lett. 2021 Feb;595(3):379-388
pubmed: 33263189
Front Plant Sci. 2019 Oct 30;10:1378
pubmed: 31737007
Methods Protoc. 2018 Jan 22;1(1):
pubmed: 31164554
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Nature. 2021 May;593(7857):142-146
pubmed: 33780970
Nature. 2021 Apr;592(7854):438-443
pubmed: 33690265
Nature. 2020 Oct;586(7830):567-571
pubmed: 32756549
J Virol. 2019 Apr 3;93(8):
pubmed: 30760570
Curr Opin Biotechnol. 2020 Feb;61:60-65
pubmed: 31765962
Curr Opin Biotechnol. 2020 Feb;61:53-59
pubmed: 31751895
Plant Biotechnol J. 2020 Feb 24;:
pubmed: 32096288
J Virol. 2002 Mar;76(6):2606-16
pubmed: 11861826
Cell. 2020 Dec 10;183(6):1735
pubmed: 33306958
Front Plant Sci. 2021 Jul 22;12:709344
pubmed: 34367227
Science. 2020 Sep 18;369(6510):1501-1505
pubmed: 32703906
BMC Biotechnol. 2012 Apr 26;12:14
pubmed: 22536810
Nat Med. 2021 Mar;27(3):440-446
pubmed: 33531709
Sci Rep. 2020 Oct 19;10(1):17698
pubmed: 33077899
Front Plant Sci. 2021 Jun 15;12:689104
pubmed: 34211491
Plant Biotechnol J. 2009 Sep;7(7):682-93
pubmed: 19627561
Vaccine. 2021 Sep 15;39(39):5513-5523
pubmed: 34454786
Lancet Microbe. 2021 Feb;2(2):e59
pubmed: 33655233
N Engl J Med. 2021 May 20;384(20):1885-1898
pubmed: 33725432
Lancet. 2021 Mar 13;397(10278):952-954
pubmed: 33581803